Jun 2026 (Q2 FY26) — Aug 12, 2026
Allogene Therapeutics Q2 FY26 — Strategic Progress in Allogeneic CAR-T and Pipeline Advancement
Read the full callAllogene Therapeutics (ALLO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Allogene Therapeutics earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 4.6 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | -1011.2 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -42.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.34 +3.08% · +$0.04
Performance +8.9% 1Y
1Y: $1.23 on 14 Oct 2025 → $1.34. High $3.06 (13 Apr 2026), low $1.05 (6 Nov 2025).
- Previous close
- $1.3
- 52-week range
- $1.05 – $3.06
- One year
- +5.51%
Overview
- Symbol
- ALLO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Allogene Therapeutics earnings calls (ALLO)
Financials
What the filings say
Net profit, year on year: +16% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | — | 5 |
| Operating profit | -72 | -60 | -65 | -57 | -45 | -42 | -46 | -47 |
| Operating margin | — | — | — | — | — | — | — | −1011.2% |
| Other income | 5 | 1 | 5 | 6 | 4 | 4 | 3 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -66 | -60 | -60 | -51 | -41 | -39 | -43 | -43 |
| EPS ($ per share) | -0.32 | — | -0.28 | -0.23 | -0.19 | — | -0.18 | -0.13 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -212 | -396 | -713 | -895 | -1,235 | -1,562 | -1,820 | -2,011 |
| Total liabilities | 71 | 89 | 148 | 126 | 155 | 131 | 127 | 123 |
| Fixed assets | 9 | 56 | 119 | 123 | 113 | 99 | 86 | 73 |
| Investments | 367 | 355 | 645 | 284 | — | — | — | — |
| Total assets | 774 | 718 | 1,228 | 1,051 | 822 | 643 | 549 | 416 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -45 | -137 | -115 | -185 | -221 | -238 | -200 | -149 |
| Cash from investing | -633 | 164 | -505 | 164 | 106 | 163 | 76 | 96 |
| Cash from financing | 771 | 59 | 634 | 12 | 3 | 96 | 117 | 30 |
| Net cash flow | 94 | 86 | 13 | -9 | -111 | 21 | -8 | -24 |
| Capital expenditure | -3 | -51 | -66 | -21 | -5 | -2 | -1 | -0 |
| Free cash flow | -48 | -188 | -181 | -206 | -226 | -239 | -201 | -150 |
Insider filings
17 filings between Oct 21, 2025 and Aug 21, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$666.3K
15 sales by 6 insiders
Compensation
not trading decisions- 2
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Chang David D | — | $289.5K | Mar 16, 2026 |
| Roberts Zachary | — | $104.2K | Feb 2, 2026 |
| Douglas Earl Martin | — | $103.3K | Aug 21, 2026 |
| Parker Geoffrey M. | — | $88.4K | Feb 2, 2026 |
| Beneski Benjamin Machinas | — | $51.7K | Mar 31, 2026 |
| Yoshiyama Annie | — | $29.3K | Apr 21, 2026 |
Latest filings (38)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Douglas Earl Martin SVP, General Counsel | Sale | 29,697 | $63.0K |
| Jun 18, 2026 | Kazam Joshua A Director | Option exercise | 47,700 | $0 |
| Apr 21, 2026 | Yoshiyama Annie SVP, Finance | Sale | 9,586 | $22.1K |
| Mar 31, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 2,867 | $7.2K |
| Mar 16, 2026 | Chang David D President and CEO | Sale | 47,763 | $118.0K |
| Mar 16, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 4,835 | $11.9K |
| Mar 2, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 7,132 | $18.5K |
| Feb 2, 2026 | Douglas Earl Martin SVP, General Counsel | Sale | 22,900 | $40.3K |
| Feb 2, 2026 | Roberts Zachary EVP of R&D | Sale | 35,700 | $63.2K |
| Feb 2, 2026 | Yoshiyama Annie SVP, Finance | Sale | 4,167 | $7.2K |
| Feb 2, 2026 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 24,001 | $42.2K |
| Feb 2, 2026 | Chang David D President and CEO | Sale | 95,269 | $171.5K |
| Feb 2, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 7,549 | $13.1K |
| Jan 21, 2026 | Roberts Zachary EVP of R&D | Sale | 26,269 | $41.0K |
| Dec 18, 2025 | Kazam Joshua A Director | Option exercise | 47,700 | $0 |
| Nov 17, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 786 | $959 |
| Oct 21, 2025 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 36,744 | $46.2K |
| Jun 10, 2025 | MESSEMER DEBORAH M. Director | Sale 10b5-1 plan | 36,885 | $52.4K |
| Apr 21, 2025 | Yoshiyama Annie SVP, Finance | Sale | 9,601 | $13.5K |
| Mar 14, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 5,488 | $10.8K |
| Mar 14, 2025 | Chang David D President and CEO | Sale | 46,668 | $91.5K |
| Mar 1, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Award | 31,755 | $0 |
| Feb 18, 2025 | MESSEMER DEBORAH M. Director | Sale 10b5-1 plan | 13,313 | $32.4K |
| Feb 3, 2025 | Roberts Zachary EVP of R&D | Sale | 18,832 | $32.0K |
| Feb 3, 2025 | Chang David D President and CEO | Sale | 46,003 | $77.3K |
| Feb 3, 2025 | MOORE TIMOTHY L. Chief Technical Officer | Sale | 14,746 | $25.2K |
| Feb 3, 2025 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 4,361 | $7.5K |
| Feb 3, 2025 | Douglas Earl Martin SVP, General Counsel | Sale | 6,404 | $11.0K |
| Jan 24, 2025 | Chang David D President and CEO | Award | 552,174 | $0 |
| Jan 24, 2025 | Belldegrun Arie Director | Award | 369,957 | $0 |
| Jan 24, 2025 | Roberts Zachary EVP of R&D | Award | 173,913 | $0 |
| Jan 24, 2025 | Yoshiyama Annie SVP, Finance | Award | 36,232 | $0 |
| Jan 24, 2025 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Award | 173,913 | $0 |
| Jan 24, 2025 | Douglas Earl Martin SVP, General Counsel | Award | 144,928 | $0 |
| Jan 21, 2025 | Roberts Zachary EVP of R&D | Sale | 27,199 | $48.4K |
| Dec 9, 2024 | MESSEMER DEBORAH M. Director | Sale 10b5-1 plan | 9,136 | $19.9K |
| Dec 5, 2024 | Humer Franz B Director | Sale | 9,221 | $19.9K |
| Oct 21, 2024 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Tax withheld | 36,404 | $103.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Allogene Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Allogene Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading